Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Troubled Realm Therapeutics Selling Assets, Delisting From London AIM

US-based, UK-listed biotech says it is talking with 'interested parties' including those considering making an offer for the business.

Business Strategies Commercial

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.

Business Strategies Commercial

US Rights Deal Will Make Proleukin Clinigen's Biggest Product

Clinigen's planned purchase of US rights to Proleukin will give it global ownership of the IL-2 drug.

Business Strategies Deals

Almirall Extends Dermatology Reach With Dermira Lebrikizumab Deal

Almirall has re-affirmed its dermatology emphasis by entering a lebrikizumab option and license pact with Dermira for treating eczema in Europe.

Deals Dermatology

China's EpimAb Advances Bispecific Antibody To Rival Janssen Candidate

EpimAb's business development officer tells Scrip dosing has started in a Phase I/II trial assessing the China-based biotech's lead cancer molecule EMB01, an EGFR-cMET bispecific antibody.

StartUps and SMEs Companies

Grey Wolf To Use £10m Series A To Illuminate Tumors For Destruction

UK's Grey Wolf Therapeutics completes £10m Series A financing for use in altering tumor cells, illuminating them for attack and destruction by the immune system.  

Financing ImmunoOncology
See All
Advertisement
UsernamePublicRestriction

Register